Skip to contentI
Immuneering Corp
I
IMRXImmuneering Corp Q1 2023 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2022 Net Income-$13.60M-$13.60MN/M vs Q1 2022 EPS Diluted-$0.51-$0.51N/M vs Q1 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immuneering Corp · CIK 1790340 · Engraved from SEC EDGAR
Operating Cash Flow-$14,418,018N/M Free Cash Flowderived-$14,446,011N/M ended Mar 31, 2023 · filed May 4, 2023 · 34 d after period end